"id","instanceType","rationale","versionIdentifier","uuid:ID"
"StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","eabc1b8b-67a1-44d3-84a2-0d4b5dc3c354"
